Carl Deutsch, PhD, MBA

Carl Deutsch, PhD, MBA has extensive experience in the pharmaceutical industry. Carl began their career in 2010 as Director of ADC Chemistry and Biology at Merck KGaA, Darmstadt, Germany. Carl then became the Founder of the inaSolve team, which won Merck's idea competition Innospire in 2018 and received funding for further development. Carl was also Associate Director Research Chemistry for Antibody Drug Conjugates, where they developed drug strategies and focus areas for antibody drug conjugates, presented strategies in upper management decision committees, and built a chemistry platform for ADCs including infrastructure, IP protected assets and collaboration/CRO network. Lastly, they were Head of Laboratory Medicinal Chemistry, where they were responsible for discovery and optimization of small molecules as drugs in oncology and immunology, running a group of 3 technicians, and coordinating CROs as extended workbench. In 2022, they became Chief Scientific Officer at NBE-Therapeutics AG.

Carl Deutsch has a diverse education history, with a Doctorate (Ph.D.) in Chemistry from TU Dortmund University (2004-2008), a Diplom in Chemistry from TU Dortmund University (1999-2008), and an Executive MBA from Mannheim Business School (2020-2022). Carl also completed internships as part of their PhD at Kyoto University (2007) and UC Santa Barbara (2005).